<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525901</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 12-0929</org_study_id>
    <secondary_id>IF# 1358648</secondary_id>
    <secondary_id>1R34MH100276-01</secondary_id>
    <secondary_id>GCO 11-1555</secondary_id>
    <secondary_id>R34MH100276</secondary_id>
    <nct_id>NCT01525901</nct_id>
  </id_info>
  <brief_title>Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)</brief_title>
  <official_title>A Double-Blind Placebo-Controlled Crossover Trial of Insulin-Like Growth Factor-1 (IGF-1) in Children and Adolescents With 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to pilot the use of Insulin-Like Growth Factor-1 (IGF-1)&#xD;
      treatment in 22q13 Deletion Syndrome (Phelan-McDermid Syndrome) caused by SHANK3 gene&#xD;
      deficiency in order to evaluate safety, tolerability, and efficacy. IGF-1 is an injection&#xD;
      under the skin that contains human IGF-1. IGF-1 is approved by the FDA under the brand name&#xD;
      Increlex for the treatment of children with short stature due to primary IGF-1 deficiency. It&#xD;
      is being used off-label in the current study and is not FDA approved, nor has it yet been&#xD;
      studied in humans for the treatment of SHANK3 deficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall, there will be 1-3 screening visits, a baseline visit where study drug will first be&#xD;
      administered, and then 10 follow-up visits. Follow-up visits will occur at week 2, week 4,&#xD;
      week 8, and week 12 in each treatment phase (IGF-1 or placebo), and then again 4 weeks after&#xD;
      study completion, Parents/guardians will be asked to administer the IGF-1/ placebo by&#xD;
      injection at home and will also be responsible for monitoring glucose levels in the child.&#xD;
      Parents/guardians will be trained in these methods, and will have scheduled phone calls and&#xD;
      appointments where the dose and tolerability will be discussed.&#xD;
&#xD;
      Assessments include the following:&#xD;
&#xD;
        -  Physical and neurological examination&#xD;
&#xD;
        -  Medical and psychiatric history&#xD;
&#xD;
        -  X-ray of long bone (e.g., hand) to ensure your child's growth plates are not closed&#xD;
&#xD;
        -  Electrocardiography&#xD;
&#xD;
        -  Echocardiography&#xD;
&#xD;
        -  Pregnancy test if applicable&#xD;
&#xD;
        -  Lab safety measures (through blood draw)&#xD;
&#xD;
        -  Autism Diagnostic Interview (ADI)&#xD;
&#xD;
        -  Autism Diagnostic Observation Schedule (ADOS)&#xD;
&#xD;
        -  The Mullen Scales of Early Learning or the Leiter International Performance&#xD;
           Scale-Revised&#xD;
&#xD;
        -  Vineland Adaptive Behavior Scale (VABS)&#xD;
&#xD;
        -  Clinical Global Impressions (CGI) Rating Scales&#xD;
&#xD;
        -  The Repetitive Behaviors Scale (RBS)&#xD;
&#xD;
        -  Aberrant Behavior Checklist (ABC)&#xD;
&#xD;
        -  The Caregiver Strain Questionnaire (CSI)&#xD;
&#xD;
        -  Language Environment Analysis (LENA)&#xD;
&#xD;
        -  The Macarthur-Bates Communication Inventory (MCDI)&#xD;
&#xD;
        -  Unified Parkinson's Disease Rating Scale (UPDRS)&#xD;
&#xD;
        -  Quick Neurological Screening Test 2nd Edition (QNST-2)&#xD;
&#xD;
        -  Gait Analysis with motion capture video systems and interactive 3-dimensional modeling&#xD;
           systems&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) subscale</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Repetitive Behavior Scale</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-Improvement and Severity Scales</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Strain Index</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory outcomes</measure>
    <time_frame>Week 12</time_frame>
    <description>Expressive language, social orienting, and motor skills,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>22q13 Deletion Syndrome</condition>
  <condition>Phelan-McDermid Syndrome</condition>
  <arm_group>
    <arm_group_label>Insulin-Like Growth Factor-1 (IGF-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin-Like Growth Factor-1 (IGF-1)</intervention_name>
    <description>IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.</description>
    <arm_group_label>Insulin-Like Growth Factor-1 (IGF-1)</arm_group_label>
    <other_name>Mecasermin; Increlex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Saline solution will be administered for three months subcutaneously.</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  5 to 12 years old&#xD;
&#xD;
          -  pathogenic deletions or mutations of the SHANK3 gene&#xD;
&#xD;
          -  stable medication regimens for at least three months prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  closed epiphyses&#xD;
&#xD;
          -  active or suspected neoplasia&#xD;
&#xD;
          -  intracranial hypertension&#xD;
&#xD;
          -  hepatic insufficiency&#xD;
&#xD;
          -  renal insufficiency&#xD;
&#xD;
          -  cardiomegaly / valvulopathy&#xD;
&#xD;
          -  history of allergy to IGF-1 or any component of the formulation (mecasermin)&#xD;
&#xD;
          -  history of extreme prematurity (&lt;1000 grams) with associated early neo-natal&#xD;
             complications, e.g. intra-cerebral hemorrhage, prolonged hypoxia, prolonged&#xD;
             hypoglycemia&#xD;
&#xD;
          -  patients with comorbid conditions deemed too medically compromised to tolerate the&#xD;
             risk of experimental treatment with IGF-1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Kolevzon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hannah Grosman</last_name>
    <phone>212-241-7098</phone>
    <email>hannah.grosman@mssm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seaver Austin Center, Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Kolevzon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.seaverautismcenter.org</url>
    <description>Seaver Autism Center</description>
  </link>
  <link>
    <url>http://www.shank3gene.org</url>
    <description>SHANK3 gene</description>
  </link>
  <link>
    <url>http://www.pmsf.org/</url>
    <description>Phelan-McDermid Syndrome Foundation</description>
  </link>
  <results_reference>
    <citation>Kolevzon A, Bush L, Wang AT, Halpern D, Frank Y, Grodberg D, Rapaport R, Tavassoli T, Chaplin W, Soorya L, Buxbaum JD. A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. Mol Autism. 2014 Dec 12;5(1):54. doi: 10.1186/2040-2392-5-54. eCollection 2014. Erratum in: Mol Autism. 2015;6:31.</citation>
    <PMID>25685306</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Alexander Kolevzon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>SHANK3</keyword>
  <keyword>IGF-1</keyword>
  <keyword>Autism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Chromosome Deletion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Mecasermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

